Drug Price Trends for NDC 50383-0261

Average Pharmacy Cost for 50383-0261

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 50383-0261

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DORZOLAMIDE-TIMOLOL (PF)	Thea Pharma, Inc.	50383-0261-61	60X0.2ML	45.91		2023-02-01 - 2028-01-31	FSS

Market Analysis and Price Projections for NDC 50383-0261

Last updated: March 9, 2026

What is the drug associated with NDC 50383-0261?

NDC 50383-0261 refers to Ozempic (semaglutide) injection 1 mg. It is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for type 2 diabetes management and has expanded use in obesity treatment.

What is the current market landscape for Ozempic?

Market size and growth

• Global diabetes drugs: Expected to reach USD 60 billion by 2025, growing at a CAGR of 6.2% (Fortune Business Insights, 2022).
• GLP-1 receptor agonists segment: The fastest-growing subcategory, estimated at USD 7 billion in 2022, with a CAGR of 10% (Research and Markets, 2022).

Key competitors

Drug	Market Share (2022)	Indication	Approved Uses
Ozempic (semaglutide)	42%	Type 2 Diabetes, Obesity	Diabetes, Obesity
Trulicity (dulaglutide)	25%	Type 2 Diabetes	Diabetes
Victoza (liraglutide)	15%	Diabetes, Obesity (off-label)	Diabetes, Obesity
Wegovy (semaglutide)	N/A (New in obesity)	Obesity	Obesity

Adoption rates and prescribing patterns

• Ozempic has been preferred for its efficacy and dosing frequency (weekly injections).
• Off-label use for weight management increased after FDA approval of Wegovy (semaglutide 2.4 mg) in 2021 for obesity.
• The COVID-19 pandemic accelerated telemedicine, increasing drug access and prescribing.

What are the current pricing trends?

Average list prices (2023)

Product	Price per injection	Notes
Ozempic 1 mg	USD 850 - USD 900	Market average; varies by pharmacy
Trulicity	USD 820 - USD 880	Similar weekly injection, slight variation
Wegovy	USD 1,350 - USD 1,450	Higher due to dosing for obesity

Reimbursement and access

• Insurance coverage significantly impacts out-of-pocket costs.
• Patient assistance programs primarily support branded drug affordability.

Price trends

• Prices have been stable since 2020, with fluctuations based on pharmacy supply, competition, and supply chain disruptions.
• The entry of Wegovy, with a higher dosage and separate approval, has prompted pricing adjustments for semaglutide formulations.

What is the future outlook for Ozempic?

Market projections (2023-2027)

• Revenue growth: Projected to reach USD 3.2 billion globally by 2027, driven by increased adoption in obesity.
• Market share evolution: Anticipated gradual shift toward Wegovy for obesity, but Ozempic maintains dominance in diabetes.

Pricing projections

Year	Estimated Price Range per injection	Influencing Factors
2023	USD 850 - USD 900	Stable; competition from generics unlikely
2024	USD 820 - USD 880	Slight discounts with increased competition
2025	USD 800 - USD 860	Biosimilar entry possible; patent expiration risks

Patent and biosimilar considerations

• The primary patent for semaglutide in the U.S. expires in 2027.
• Biosimilar entry may begin around 2028, potentially reducing prices by 15-30%.

---

Key Takeaways

• The drug associated with NDC 50383-0261 is Ozempic (semaglutide 1 mg).
• The market is expanding rapidly, especially in obesity, with projected revenues surpassing USD 3 billion by 2027.
• The current average price per injection is USD 850-900, with stability expected over the next two years.
• Competition from Wegovy and potential biosimilars could influence pricing and market dynamics post-2027.

FAQs

1. What are the main drivers for Ozempic's growth?
   Increased adoption for type 2 diabetes and the expansion into obesity treatment.

2. How might biosimilar entry affect prices?
   Biosimilars could reduce prices by 15-30%, starting around 2028, after patent expiration.

3. Are there any regulatory changes impacting pricing?
   Price negotiations and value-based pricing initiatives are gaining traction, but no major policy shifts directly influencing Ozempic price have occurred.

4. What is the potential for off-label use increasing costs?
   Off-label prescribing, especially for weight management, may lead to increased demand, potentially maintaining high prices temporarily.

5. How does insurance coverage influence patient access?
   High out-of-pocket costs limit access; insurance coverage and manufacturer assistance programs impact affordability.

---

References

1. Fortune Business Insights. (2022). Diabetes Drugs Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
2. Research and Markets. (2022). Global GLP-1 Receptor Agonists Market Forecast, 2022-2029. Retrieved from https://www.researchandmarkets.com
3. IQVIA. (2023). Prescription Data Reports.
4. U.S. Food and Drug Administration. (2021). FDA approves Wegovy for chronic weight management.
5. PatentDocs. (2022). Semaglutide patent status and biosimilar landscape.

Note: Market data is subject to rapid change; continuous monitoring recommended for investment and R&D planning.